Ligand Pharmaceuticals LGND Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $268.09M+60.4% | $167.13M+27.3% | $131.31M-33.1% | $196.25M-18.8% | ||
| $81.18M+279% | $21.43M-12.7% | $24.54M-32.0% | $36.08M+12.4% | ||
| $92.45M+17.5% | $78.65M+49.0% | $52.79M-24.7% | $70.06M+49.7% | ||
| $227.09M+19.7% | $189.74M+56.2% | $121.49M-37.1% | $193.21M+40.3% | ||
| $41M+281% | -$22.61M— | —— | —— | ||
| 15.3%+28.8pp | -13.5%— | —— | —— | ||
| $4.72M+55.5% | $3.03M+362% | $656K-63.5% | $1.8M-90.8% | ||
| $117.96M— | —— | $51.72M+56.8% | $32.97M+204% | ||
| $158.96M— | —— | $63.66M+76.8% | $36.01M-50.1% | ||
| $34.51M— | —— | —— | $41.23M— | ||
| $124.45M+3,187% | -$4.03M-108% | $52.15M+256% | -$33.36M-158% | ||
| 46.4%+48.8pp | -2.4%-42.1pp | 39.7%+56.7pp | -17%-40.7pp | ||
| $5.89+3,045% | -$0.20-107% | $2.90+261% | -$1.80-152% | ||
| $74.78M+492% | $12.63M-81.7% | $69.05M-30.3% | $99.05M-36.1% | ||
| 27.9%+20.3pp | 7.6%-45.0pp | 52.6%+2.1pp | 50.5%-13.7pp | ||
| $41M+281% | -$22.61M-169% | $32.53M-31.5% | $47.52M-54.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Ligand Pharmaceuticals's profit margins?
- Gross margin is 91.9% and operating margin is 34.5%, with a 55.9% net margin.
- Where does Ligand Pharmaceuticals's income statement data come from?
- Every line is extracted from Ligand Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.